Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
| Market Cap | $1.21B-67.9% |
| Revenue (ttm) | $0 |
| Net Income | -$369.97M-115.9% |
| EPS | -$4.36-47.8% |
| Shares Out | 88.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,345,618 |
| Open | $13.81 |
| Previous Close | $14.16 |
| Day's Range | $13.57 - $14.74 |
| 52-Week Range | $13.57 - $44.13 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | $29.00(+112.30%) |
| Earnings Date | Mar 11, 2027 |
About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating MLYS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 11, 2027Earnings report
$MLYS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MLYS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MLYS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MLYS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MLYS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MLYS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MLYS
| VTIVanguard Morningstar Total Stock Market ETF | $30.20M |
| IWMiShares Russell 2000 ETF | $22.51M |
| XBIState Street SPDR S&P Biotech ETF | $21.32M |
| VXFVanguard Extended Market ETF | $13.76M |
| IWOiShares Russell 2000 Growth ETF | $8.16M |
| IBBiShares Biotechnology ETF | $6.69M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MLYS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive clinical trial data for lorundrostat showing sustained efficacy with FDA milestone and stock price gains indicate bullish sentiment.
Recent Insider Activity
Insider Score Trend Over Time
-46.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 0.90% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.51% |
| TDNA | T. Rowe Price Biotech ETF | 0.49% |
| HELX | Franklin Genomic Advancements ETF | 0.26% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.23% |
| XBI | State Street SPDR S&P Biotech ETF | 0.23% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.23% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.15% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.10% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.10% |
| ESSC | Eventide Small Cap ETF | 0.09% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
